Effect of Tetrabenazine on Stroop Interference in HD
|ClinicalTrials.gov Identifier: NCT01834911|
Recruitment Status : Completed
First Posted : April 18, 2013
Last Update Posted : April 2, 2018
|Condition or disease||Intervention/treatment||Phase|
|Huntington Disease||Drug: Tetrabenazine withdrawal||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Tetrabenazine on Stroop Interference in Huntington Disease|
|Actual Study Start Date :||March 2013|
|Actual Primary Completion Date :||January 1, 2018|
|Actual Study Completion Date :||January 1, 2018|
Experimental: Tetrabenazine withdrawal
Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
Drug: Tetrabenazine withdrawal
Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
- Change in Stroop Interference Score [ Time Frame: 6 hours ]Participants will have Stroop Visual Interference Scores measured while OFF tetrabenazine for at least 3 days. Two doses of 12.5 mg tetrabenazine will be subsequently administered: first dose just after the Stroop test and second dose 3 hours later. Stroop Visual Interference Scores will be measured again in the ON state, 6 hours after the initial OFF measurement.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01834911
|United States, New York|
|Terence Cardinal Cooke Health Care Center|
|New York, New York, United States, 10029|